1. Home
  2. MLYS vs VREX Comparison

MLYS vs VREX Comparison

Compare MLYS & VREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • VREX
  • Stock Information
  • Founded
  • MLYS 2019
  • VREX 2016
  • Country
  • MLYS United States
  • VREX United States
  • Employees
  • MLYS N/A
  • VREX N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • VREX Industrial Machinery/Components
  • Sector
  • MLYS Health Care
  • VREX Technology
  • Exchange
  • MLYS Nasdaq
  • VREX Nasdaq
  • Market Cap
  • MLYS 890.6M
  • VREX 483.7M
  • IPO Year
  • MLYS 2023
  • VREX N/A
  • Fundamental
  • Price
  • MLYS $37.29
  • VREX $11.60
  • Analyst Decision
  • MLYS Strong Buy
  • VREX Strong Buy
  • Analyst Count
  • MLYS 6
  • VREX 2
  • Target Price
  • MLYS $42.60
  • VREX $19.50
  • AVG Volume (30 Days)
  • MLYS 2.6M
  • VREX 336.5K
  • Earning Date
  • MLYS 11-10-2025
  • VREX 08-07-2025
  • Dividend Yield
  • MLYS N/A
  • VREX N/A
  • EPS Growth
  • MLYS N/A
  • VREX N/A
  • EPS
  • MLYS N/A
  • VREX N/A
  • Revenue
  • MLYS N/A
  • VREX $821,400,000.00
  • Revenue This Year
  • MLYS N/A
  • VREX $5.01
  • Revenue Next Year
  • MLYS N/A
  • VREX $2.97
  • P/E Ratio
  • MLYS N/A
  • VREX N/A
  • Revenue Growth
  • MLYS N/A
  • VREX N/A
  • 52 Week Low
  • MLYS $8.24
  • VREX $6.76
  • 52 Week High
  • MLYS $39.20
  • VREX $16.93
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 82.81
  • VREX 61.49
  • Support Level
  • MLYS $34.59
  • VREX $10.85
  • Resistance Level
  • MLYS $39.20
  • VREX $11.74
  • Average True Range (ATR)
  • MLYS 2.83
  • VREX 0.48
  • MACD
  • MLYS 0.73
  • VREX -0.11
  • Stochastic Oscillator
  • MLYS 92.13
  • VREX 69.83

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About VREX Varex Imaging Corporation

Varex Imaging Corp designs and manufactures X-ray imaging components. It operates in two segments Medical and Industrial. The Medical segment, which is the key revenue driver, designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, digital detectors and accessories, generators, and heat exchangers among other products. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high-voltage connectors, and coolers. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA) and the rest from the Americas and Asia Pacific region.

Share on Social Networks: